Skip to main content
Captor Therapeutics S.A. logo

Captor Therapeutics S.A. — Investor Relations & Filings

Ticker · CTX ISIN · PLCPTRT00014 LEI · 259400JHH1S2I2S4O735 WAR Professional, scientific and technical activities
Filings indexed 920 across all filing types
Latest filing 2025-11-27 Director's Dealing
Country PL Poland
Listing WAR CTX

About Captor Therapeutics S.A.

https://www.captortherapeutics.com/

Captor Therapeutics is a biopharmaceutical company focused on the discovery and development of novel therapeutics for diseases with high unmet medical needs. The company specializes in Targeted Protein Degradation (TPD), a technology that enables the elimination of disease-causing proteins previously considered "undruggable." Its core research and development activities are centered on creating new treatments for cancer and autoimmune diseases. To achieve this, Captor Therapeutics utilizes its proprietary Optigrade™ platform. This integrated drug discovery engine combines advanced technologies, including structural biology, proteomics, molecular modeling, and protein engineering, to identify and optimize novel drug candidates. The platform is designed to accelerate the development of degraders with superior therapeutic properties, aiming to provide new treatment options for severe conditions.

Recent filings

Filing Released Lang Actions
Informacja o transakcji na akcjach Spółki uzyskana w trybie art. 19 MAR - Content (PL)
Director's Dealing Classification · 100% confidence The document is a short notification from the company regarding a transaction on company shares by a member of the Supervisory Board (Paweł Holstinghausen Holsten). This is a standard disclosure of insider trading/director dealing as required by the MAR (Market Abuse Regulation).
2025-11-27 Polish
załącznik
Director's Dealing Classification · 100% confidence The document is a formal notification of a transaction by a person discharging managerial responsibilities (PDMR), specifically the Chief Financial Officer (Dyrektor ds. Finansowych) of Captor Therapeutics. It explicitly references Article 19(1) of the Market Abuse Regulation (MAR) and details the acquisition of company shares. This falls under the category of Director's Dealing (DIRS).
2025-11-27 Polish
Informacja o transakcji na akcjach Spółki uzyskana w trybie art. 19 MAR - Content (PL)
Director's Dealing Classification · 100% confidence The document is a notification regarding a transaction on company shares by the Chief Financial Officer (Dyrektor ds. Finansowych). It explicitly references Article 19 of the MAR (Market Abuse Regulation) regarding insider transactions. This fits the definition of a Director's Dealing (DIRS) report, which covers personal share transactions by company executives.
2025-11-27 Polish
załącznik
Director's Dealing Classification · 100% confidence The document is a formal notification of a transaction by a person discharging managerial responsibilities (PDMR), specifically the CEO (Prezes Zarządu) of Captor Therapeutics. It follows the standard template required by Article 19 of the Market Abuse Regulation (MAR) for reporting insider dealings. This falls directly under the 'Director's Dealing' category.
2025-11-25 Polish
Informacja o transakcji na akcjach Spółki uzyskana w trybie art. 19 MAR - Content (PL)
Director's Dealing Classification · 100% confidence The document is a notification regarding a transaction in company shares by a director (Michał Walczak, CEO/CSO). It explicitly mentions receiving a notification under Article 19 of the MAR (Market Abuse Regulation) regarding the purchase of shares. This fits the definition of a Director's Dealing (DIRS) report.
2025-11-25 Polish
Śródroczne skrócone skonsolidowane oraz jednostkowe sprawozdanie finansowe sporządzone za okres 9 miesięcy zakończony 30 września 2025 r.
Regulatory Filings
2025-11-20 Polish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.